tiprankstipranks
Trending News
More News >
Materialise NV (MTLS)
NASDAQ:MTLS
Advertisement

Materialise (MTLS) AI Stock Analysis

Compare
896 Followers

Top Page

MTLS

Materialise

(NASDAQ:MTLS)

Rating:66Neutral
Price Target:
$5.50
▲(9.78% Upside)
Materialise's overall stock score is influenced by strong financial performance and growth in the Medical segment, despite challenges in Manufacturing and Software. The technical indicators suggest potential bearish sentiment, but the company's strategic investments and partnerships provide a positive outlook. The valuation reflects growth prospects, though it comes at a premium.

Materialise (MTLS) vs. SPDR S&P 500 ETF (SPY)

Materialise Business Overview & Revenue Model

Company DescriptionMaterialise NV provides additive manufacturing and medical software, and 3D printing services in the Americas, Europe and Africa, and the Asia-Pacific. The company operates through three segments: Materialise Software, Materialise Medical, and Materialise Manufacturing. Its Materialise Software segment offers software through programs and platforms that enable and enhance the functionality of 3D printers and of 3D printing operations. Its software interfaces between various types of 3D printers; and various software applications and capturing technologies, including computer-aided design/computer-aided manufacturing packages and 3D scanners. This segment serves 3D printing machine manufacturers; production companies and contract manufacturers in automotive, aerospace, consumer goods, and hearing aid industries; and 3D printing service bureaus through its sales force, Website, and third-party distributors. The company's Materialise Medical segment provides medical software that allows medical-image based analysis and engineering, as well as patient-specific design of surgical devices and implants. It serves medical device companies, hospitals, universities, research institutes, and industrial companies through its direct sales force, Website, and picture archiving and communication system partners. Its Materialise Manufacturing segment provides 3D printing services, design and engineering services, and rapid prototyping and additive manufacturing of production parts to industrial and commercial customers. The company has collaboration agreements with Zimmer Biomet Holdings, Inc.; Encore Medical, L.P.; DePuy Synthes Companies of Johnson & Johnson; Limacorporate Spa; Mathys AG; Corin Ltd; Medtronic Inc.; and Abbott Laboratories Inc. Materialise NV was incorporated in 1990 and is headquartered in Leuven, Belgium.
How the Company Makes MoneyMaterialise generates revenue through multiple streams, primarily from software licensing and service fees. The software segment includes sales from its proprietary software solutions that assist in the design and preparation of 3D printing processes, with recurring revenue from licenses and subscriptions. Additionally, the company earns significant income from its 3D printing services, providing custom manufacturing solutions for clients across various industries. Materialise also engages in partnerships with major players in the 3D printing ecosystem, enhancing its market reach and capabilities, further contributing to its revenue. The company's focus on innovation and expansion into new markets, such as healthcare applications, also plays a critical role in driving its financial growth.

Materialise Earnings Call Summary

Earnings Call Date:Jul 24, 2025
(Q2-2025)
|
% Change Since: -18.93%|
Next Earnings Date:Oct 23, 2025
Earnings Call Sentiment Neutral
The earnings call presented several positive developments, particularly in the Medical segment with strong growth and strategic partnerships. However, these were offset by declines in consolidated revenue and challenges in the Manufacturing segment, along with financial impacts from foreign exchange fluctuations. The sentiment is a balance between the positive medical advancements and the negative pressures from other business areas.
Q2-2025 Updates
Positive Updates
Medical Segment Growth
Materialise Medical achieved high double-digit growth with revenue increasing by almost 17% this quarter, posting a quarterly revenue record. The segment's adjusted EBITDA margin increased to 32.7%.
Gross Profit Margin Improvement
Gross profit margin increased to 58.3% in the second quarter, up from 57% the previous year, reflecting production efficiencies and changes in revenue mix.
Pilot Collaboration with Johnson & Johnson
Materialise announced a pilot collaboration with Johnson & Johnson's Surgical business in EMEA to advance the adoption of its Mimics thoracic planner solution in the respiratory market.
Positive Free Cash Flow
Materialise generated a positive free cash flow, which led to a net cash position of EUR 63 million at the end of Q2, an increase of EUR 2 million versus the beginning of the year.
Negative Updates
Consolidated Revenue Decline
Total consolidated revenue decreased year-over-year by 5.8% to EUR 64.8 million, primarily due to declines in the Software and Manufacturing segments.
Manufacturing Segment Challenges
Manufacturing revenue decreased by almost 25% compared to last year, driven by geopolitical uncertainty and macroeconomic headwinds.
Foreign Exchange Impact
The net financial result for the quarter was negatively impacted by foreign exchange fluctuations amounting to minus EUR 3.3 million.
Company Guidance
During Materialise NV's Second Quarter 2025 Financial Results Conference Call, the company provided guidance reflecting the ongoing geopolitical volatility and macroeconomic uncertainty impacting the business climate. They revised their full-year 2025 revenue guidance from the previously communicated range of EUR 270 million to EUR 285 million, down to EUR 265 million to EUR 280 million. Despite this slight reduction in revenue outlook, the company reaffirmed their adjusted EBIT guidance, maintaining it between EUR 6 million and EUR 10 million for the fiscal year. This decision was underpinned by the company's confidence in their operational cost efficiencies and the solid fundamentals of their business. Additionally, Materialise reported a strong balance sheet with a net cash position of EUR 63 million at the end of the second quarter, an increase of EUR 2 million since the beginning of the year, indicating robust cash flow management amidst challenging market conditions.

Materialise Financial Statement Overview

Summary
Materialise demonstrates solid financial performance with consistent revenue growth and improving profitability. The balance sheet is strong, with low leverage and robust cash generation, despite some volatility in free cash flow. Challenges include pressures on operational efficiency and potential liquidity constraints.
Income Statement
75
Positive
Materialise has shown a consistent growth trajectory in total revenue over the years, with a notable increase from $170.4M in 2020 to $269.9M in TTM 2025. The gross profit margin remains strong at 56.3% in TTM, and the net profit margin has improved to 3.6% from negative levels in 2022. However, EBIT margin has decreased to 2.3% in TTM, indicating pressures on operational efficiency. EBITDA margin is solid at 11.8%, showing stable earnings before non-cash expenses.
Balance Sheet
70
Positive
The company maintains a healthy balance sheet with a debt-to-equity ratio of 0.15, suggesting a conservative leverage approach. The equity ratio stands at 63.7% in TTM, indicating strong equity financing. Return on Equity has improved to 3.9% in TTM, reflecting better profitability. However, the decrease in cash and short-term investments over the years indicates potential liquidity constraints.
Cash Flow
68
Positive
Operating cash flow to net income ratio is robust at 3.2 in TTM, highlighting strong cash generation relative to net income. However, free cash flow growth has been volatile, with TTM free cash flow at $5.8M, a slight improvement from previous periods. The free cash flow to net income ratio is lower at 0.6, indicating less cash available for expansion or dividends.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue269.86M266.76M256.13M232.02M205.45M170.45M
Gross Profit151.81M150.82M145.13M128.76M117.28M94.00M
EBITDA31.88M31.24M30.09M23.44M36.72M13.75M
Net Income9.58M13.44M6.72M-2.15M13.15M-7.27M
Balance Sheet
Total Assets390.45M396.34M396.63M411.26M413.41M327.67M
Cash, Cash Equivalents and Short-Term Investments104.18M102.30M127.57M140.87M196.03M111.54M
Total Debt36.44M41.28M64.40M80.98M99.11M115.11M
Total Liabilities141.75M147.84M160.04M182.33M180.83M194.56M
Stockholders Equity248.79M248.58M236.65M228.96M232.58M133.10M
Cash Flow
Free Cash Flow5.76M5.08M8.40M-64.00K14.12M12.33M
Operating Cash Flow30.78M31.46M20.16M24.71M25.84M29.98M
Investing Cash Flow-27.78M-28.59M-11.04M-53.92M-13.13M-28.27M
Financing Cash Flow-27.03M-27.64M-22.37M-24.87M71.16M-16.89M

Materialise Technical Analysis

Technical Analysis Sentiment
Negative
Last Price5.01
Price Trends
50DMA
5.47
Negative
100DMA
5.26
Negative
200DMA
6.16
Negative
Market Momentum
MACD
-0.13
Negative
RSI
38.35
Neutral
STOCH
25.85
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MTLS, the sentiment is Negative. The current price of 5.01 is below the 20-day moving average (MA) of 5.13, below the 50-day MA of 5.47, and below the 200-day MA of 6.16, indicating a bearish trend. The MACD of -0.13 indicates Negative momentum. The RSI at 38.35 is Neutral, neither overbought nor oversold. The STOCH value of 25.85 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for MTLS.

Materialise Risk Analysis

Materialise disclosed 72 risk factors in its most recent earnings report. Materialise reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Materialise Peers Comparison

Overall Rating
UnderperformOutperform
Sector (61)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
70
Outperform
$299.00M49.2814.17%0.44%9.73%22.33%
66
Neutral
$300.06M48.462.21%3.63%-48.48%
61
Neutral
$34.98B7.37-10.82%1.91%8.82%-8.66%
61
Neutral
$304.18M1.73-10.56%9.38%-17.17%497.89%
59
Neutral
$373.00M-55.85%4.06%57.50%
54
Neutral
$343.18M-3.84%-3.34%48.15%
48
Neutral
$235.96M-105.81%-10.85%-15.09%
* Technology Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
MTLS
Materialise
5.25
-0.32
-5.75%
TRAK
ReposiTrak
16.84
-1.80
-9.66%
API
Agora
3.53
1.44
68.90%
CMRC
Commerce.com
4.85
-1.20
-19.83%
MKTW
MarketWise
17.60
2.83
19.16%
NRDY
Nerdy
1.37
0.27
24.55%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 25, 2025